Literature DB >> 36186232

Ovarian teratoid carcinosarcoma with a PIK3CA mutation: a case report and review of the literature.

Masato Aoki1, Hisamitsu Takaya1, Tomoyuki Otani2, Hidekatsu Nakai1, Kosuke Murakami1, Noriomi Matsumura1.   

Abstract

Ovarian teratoid carcinosarcoma involves an epithelial tumor of the Müllerian duct and an immature neuroepithelium, which is a characteristic of immature teratomas. Here, we describe the case of a 60-year-old woman who underwent surgery for a stage IC3 ovarian malignancy. The tumor showed a variety of histological features, including clear cell carcinoma, immature teratoma, and rhabdomyosarcoma, and a PIK3CA mutation was detected at the same locus in each. Two months after surgery and before the start of chemotherapy, multiple bone and liver metastases were found. Four courses of combination therapy with vincristine, actinomycin D and cyclophosphamide, the standard chemotherapy regimen for pediatric rhabdomyosarcoma, were administered, and a complete response was achieved. After a 2-month rest period, the patient developed recurrent peritoneal dissemination and underwent 6 courses of paclitaxel, carboplatin, and bevacizumab chemotherapy, resulting in a partial response. This is the eighth reported case of ovarian teratoid carcinosarcoma. This tumor has a very aggressive course, but initially responds to chemotherapy. However, survival over 5 years has not been reported, and elucidation of the pathogenesis and development of new treatment methods are needed. Supplementary Information: The online version contains supplementary material available at 10.1007/s13691-022-00571-w.
© The Author(s) under exclusive licence to The Japan Society of Clinical Oncology 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Entities:  

Keywords:  Clear cell carcinoma; Immature neuroepithelial tumor; PIK3CA; Rhabdomyosarcoma; Teratoid carcinosarcoma

Year:  2022        PMID: 36186232      PMCID: PMC9522960          DOI: 10.1007/s13691-022-00571-w

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  15 in total

1.  Malignant mixed müllerian tumor of the ovary with prominent neuroectodermal differentiation (teratoid carcinosarcoma).

Authors:  R L Ehrmann; N Weidner; W R Welch; I Gleiberman
Journal:  Int J Gynecol Pathol       Date:  1990       Impact factor: 2.762

2.  Teratoid carcinosarcoma of the ovary with prominent neuroectodermal differentiation.

Authors:  A Tanimoto; N Arima; R Hayashi; T Hamada; Y Matsuki; Y Sasaguri
Journal:  Pathol Int       Date:  2001-10       Impact factor: 2.534

3.  Ovarian yolk sac tumors in older women arising from epithelial ovarian tumors or with no detectable epithelial component.

Authors:  Lawrence M Roth; Aleksander Talerman; Tally Levy; Oleg Sukmanov; Bernard Czernobilsky
Journal:  Int J Gynecol Pathol       Date:  2011-09       Impact factor: 2.762

4.  Malignant mixed müllerian tumors: an immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation.

Authors:  E George; J C Manivel; L P Dehner; M R Wick
Journal:  Hum Pathol       Date:  1991-03       Impact factor: 3.466

Review 5.  Ovarian malignant mixed mullerian tumor with primitive neuroectodermal differentiation: case report with review of the literature.

Authors:  Haitham Nasser; Robert T Morris; Lamia Fathallah
Journal:  Pathol Res Pract       Date:  2010-10-14       Impact factor: 3.250

Review 6.  The development of VAC chemotherapy in rhabdomyosarcoma: what does one do for an encore?

Authors:  Frederick B Ruymann
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

7.  Malignant ovarian tumor composed of endometrioid adenocarcinoma, clear cell adenocarcinoma, squamous cell carcinoma, yolk sac tumor and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation: a case study.

Authors:  Yoshihiro Ohishi; Tsunehisa Kaku; Eisuke Kaneki; Norio Wake; Masazumi Tsuneyoshi
Journal:  Gynecol Oncol       Date:  2007-03-06       Impact factor: 5.482

8.  Molecular characterization of uterine and ovarian tumors with mixed epithelial and germ cell features confirms frequent somatic derivation.

Authors:  Stephanie L Skala; Chia-Jen Liu; Aaron M Udager; Andrew P Sciallis
Journal:  Mod Pathol       Date:  2020-05-13       Impact factor: 7.842

9.  Ovarian Teratoid Carcinosarcoma Is an Aggressive Tumor of Probable Mullerian Derivation with a Carcinosarcomatous and Mixed Germ-Cell Morphology.

Authors:  Courtney Fox; Nichole Allen; Veronica Schimp; John Maksem
Journal:  Case Rep Oncol       Date:  2019-03-19

10.  Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma.

Authors:  Hisham Abou-Taleb; Ken Yamaguchi; Noriomi Matsumura; Ryusuke Murakami; Hidekatsu Nakai; Koichiro Higasa; Yasuaki Amano; Kaoru Abiko; Yumiko Yoshioka; Junzo Hamanishi; Masafumi Koshiyama; Tsukasa Baba; Ryo Yamada; Fumihiko Matsuda; Ikuo Konishi; Masaki Mandai
Journal:  Oncotarget       Date:  2016-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.